

## Life PBR and the treatment of reinsurance Update and insider perspectives

Jason Kehrberg, FSA, MAAA Scott O'Neal, FSA, MAAA Chris Whitney, FSA, MAAA

September 1, 2020





## **SOCIETY OF ACTUARIES Antitrust Compliance Guidelines**

Active participation in the Society of Actuaries is an important aspect of membership. While the positive contributions of professional societies and associations are well-recognized and encouraged, association activities are vulnerable to close antitrust scrutiny. By their very nature, associations bring together industry competitors and other market participants.

The United States antitrust laws aim to protect consumers by preserving the free economy and prohibiting anti-competitive business practices; they promote competition. There are both state and federal antitrust laws, although state antitrust laws closely follow federal law. The Sherman Act, is the primary U.S. antitrust law pertaining to association activities. The Sherman Act prohibits every contract, combination or conspiracy that places an unreasonable restraint on trade. There are, however, some activities that are illegal under all circumstances, such as price fixing, market allocation and collusive bidding.

There is no safe harbor under the antitrust law for professional association activities. Therefore, association meeting participants should refrain from discussing any activity that could potentially be construed as having an anti-competitive effect. Discussions relating to product or service pricing, market allocations, membership restrictions, product standardization or other conditions on trade could arguably be perceived as a restraint on trade and may expose the SOA and its members to antitrust enforcement procedures.

While participating in all SOA in person meetings, webinars, teleconferences or side discussions, you should avoid discussing competitively sensitive information with competitors and follow these guidelines:

- **Do not** discuss prices for services or products or anything else that might affect prices
- **Do not** discuss what you or other entities plan to do in a particular geographic or product markets or with particular customers.
- Do not speak on behalf of the SOA or any of its committees unless specifically authorized to do so.
- **Do** leave a meeting where any anticompetitive pricing or market allocation discussion occurs.
- Do alert SOA staff and/or legal counsel to any concerning discussions
- Do consult with legal counsel before raising any matter or making a statement that may involve competitively sensitive information.

Adherence to these guidelines involves not only avoidance of antitrust violations, but avoidance of behavior which might be so construed. These guidelines only provide an overview of prohibited activities. SOA legal counsel reviews meeting agenda and materials as deemed appropriate and any discussion that departs from the formal agenda should be scrutinized carefully. Antitrust compliance is everyone's responsibility; however, please seek legal counsel if you have any questions or concerns.



#### **Presentation Disclaimer**

Presentations are intended for educational purposes only and do not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually and, unless expressly stated to the contrary, are not the opinion or position of the Society of Actuaries, its cosponsors or its committees. The Society of Actuaries does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented. Attendees should note that the sessions are audio-recorded and may be published in various media, including print, audio and video formats without further notice.




## **Agenda**

- 1. Background
- 2. Field Study
- 3. Range of Interpretation Survey
- 4. Key Takeaways
- 5. Current Status and Additional Resources

Scott O'Neal, FSA, MAAA September 1, 2020



## **Project Overview**



#### Field Test

 Participants provide projected results under different APFs and scenarios

#### Range of Interpretation Survey

 Poll participants to describe how they would implement each of the proposed solutions (APFs)

#### Representative PBR Model

- Validate and interpret Field Test and Survey output
- Utilize Representative PBR Model to extend understanding of results



## **Introduction to Proposed Solutions**

## "Principles" APF 2019-40

 Model YRT premiums using anticipated experience with margins based on clarified modeling principles/guidance and actuarial judgment

#### "Best Estimate" APF 2019-41

- Premiums determined using current YRT premium scale with projected adjustments based on what the company actually expects will occur
- Claims determined using the company's anticipated experience mortality assumptions including mortality improvement

## "Prescribed Margin" APF 2019-42

 Non-guaranteed reinsurance premiums are modeled as the current scale plus a margin, which is developed based on prescribed inputs, with some flexibility to make adjustments to reflect contract provisions



## **Field Study Overview**

#### Submission requirements

Compute point-in-time and projected reserves for Term and/or ULSG products, using the 2020 Valuation Manual with modifications to the treatment of non-guaranteed reinsurance

Produce modeled results and detailed disclosures for two baseline runs and each proposed solution with modification per testing scenarios

#### **Participation**

187	Entities	invited t	o partici <sub>l</sub>	pate
-----	----------	-----------	------------------------	------

11 Participating entities

O Participating reinsurers

**7** Submissions for Term

**8** Submissions for ULSG

#### Representative PBR Model Key Dimensions

#### YRT Rate Scale Analysis

- Baseline YRT Scale: YRT scale in line with anticipated mortality excluding future mortality improvement (FMI)
- Lower YRT Scale: YRT scale reflective of future mortality improvement
- Higher YRT Scale: YRT scale greater than anticipated mortality without FMI

#### **Credibility Levels**

- **High Credibility** Scenario (100% Credibility)
- Low Credibility Scenario (50% Credibility)



### **Field Test Scenarios**

Baseline

- Interim solution (1/2 Cx)
- No Change to current YRT rates

2019-40


- Action A No change in YRT rates and counterparty actions
- Action B Prudent estimate YRT rates and counterparty actions
- Action C Prudent estimate YRT rates after reaching a Loss Trigger
- Action D Prudent estimate YRT rates after consecutive years of Loss Trigger


2019-41

 Anticipated experience mortality includes 15 years of future mortality improvement at rates of 0%, 0.5% and 1.0%

2019-42

 Anticipated experience mortality includes future mortality improvement for a specified number of years (5, 10, 15 and 20 years) **3.1** ULSG Gross DR – Net DR (per 1000 of projected ceded NAAR)









### **APF 2019-40 Field Test Results**

**3.1** ULSG Gross DR – Net DR (per 1000 of projected ceded NAAR) *No change to YRT rates (Baseline)* 




#### Commentary


- Both Action B and Action C reduced the overall range of modeled "DR Reserve Credits" seen in field test participant results
- Action B saw large reductions to the upper end of the "DR Reserve Credit" range, but saw an increase to the lower end of the range – particularly as shown by the PBR Representative Model results
- The loss ratio mechanism of Action C greatly reduced the high and low end of the range of field test and PBR Representative Model results



**3.6** ULSG Gross DR – Net DR (per 1000 of projected ceded NAAR) Action B - Prudent estimate YRT rates and counterparty actions




**3.8** ULSG Gross DR – Net DR (per 1000 of projected ceded NAAR) Action C - Prudent estimate YRT rates after reaching a Loss Trigger





### **APF 2019-41 Field Test Results**

**3.1** ULSG Gross DR – Net DR (per 1000 of projected ceded NAAR) *No change to YRT rates (Baseline)* 




#### Commentary


- Field test instructions asked participants to model different levels of future mortality improvement applied to reinsurance claim settlements only
- The representative PBR model included margins in addition to YRT premiums as a modeling simplification rather than a pure interpretation of the APF
- 50bps of incremental mortality improvement reduces the DR "reserve credit" to close to zero in initial projection years for the "Baseline YRT scale"



#### **3.11** ULSG Gross DR – Net DR (per 1000 of projected ceded NAAR)




### **3.12** ULSG Gross DR – Net DR (per 1000 of projected ceded NAAR) 0.5% FMI for 15 years





## **APF 2019-42 Field Test Results**

**3.1** ULSG Gross DR – Net DR (per 1000 of projected ceded NAAR) *No change to YRT rates (Baseline)* 




#### Commentary


- APF 2019-41 and APF 2019-42 produce similar results, with main variations driven by the application of mortality improvement (magnitude and length)
- 5-years of incremental mortality improvement reduces the DR "reserve credit" by roughly 50%
- When a margin is defined as the relationship between anticipated experience and best estimate mortality, "Higher YRT rate scales" lead to negative reserve credits



 $\bf 3.14~ULSG~Gross~DR-Net~DR~(per~1000~of~projected~ceded~NAAR)$ 



**3.16** ULSG Gross DR – Net DR (per 1000 of projected ceded NAAR) 15 vears FMI





## **Range of Interpretation Survey Introduction**

51 legal entity responses to survey

36 separate direct writers and reinsurers

55% of industry by new business face amount

#### **Survey Purpose**

- Poll companies on the modeling approach they would use to implement APFs
- Supplement and broaden range of practice outside of the participation of field test responses
- Collect separate responses for different treatment by treaty type

#### **Survey Response Choices**

- None Maintain the current scale throughout the projection
- Reactive Increase by a percent of the prescribed margin after X years
- Breakeven Increase by percent of difference between PBR mortality and current scale of YRT rates

The Representative PBR Model was utilized to analyze surveyed approaches for each APF. To focus on the impact of different approaches, the Baseline YRT scale and High Credibility was used in the model.



## APF 2019-40 | Survey Results

Reinsurer Reaction	Survey %		
None	19%		
Reactive	40%		
Break-even	25%		
Other	16%		

No change to YRT premiums

*Increase YRT premiums by* 

- 100% of prescribed mortality margin after 1 year and every year thereafter
- Includes implicit margin assuming future mortality improvement in all years

#### Increase YRT premiums by

 100% of the difference between current YRT premium and prescribed mortality immediately and every year thereafter

#### Commentary

- APF 2019-40 had the most variation in survey responses
- Responses ranged from straightforward (reactive or break-even) to complex
- The largest "DR Reserve Credit" produced by the representative model was from the "None" reinsurer reaction
- The reactive scenario with the implicit margin including all years of FMI creates a negative "DR Reserve Credit"

**4.3** ULSG Pre-reinsurance DR – Post-reinsurance DR (projected reserves) "Baseline YRT scale" and high credibility

1.0
0.8
0.6
0.4
0.2
0.0
-0.2
-0.4
0 5 10 15 20 25 30 35 40 45 50 55 60



## APF 2019-41 | Survey Results

Reinsurer Reaction	Survey %		
None	55%		
Reactive	17%		
Break-even	18%		
Other	10%		

#### **Modeling Details**

 No change to YRT premiums


Increase YRT premiums by

 100% of the difference between current YRT premium and prescribed mortality immediately and every year thereafter

#### Commentary

- Most responses were either None or Break-even
- Many responses indicated the need for multiple models or runs to apply this APF to reflect best estimate mortality for reinsurance cash flows and VM-20 mortality for all other cash flows
- The smallest range in modeled "DR Reserve Credits" was due to high alignment between the YRT scale w/ margin and the mortality used for reinsurance claim settlements

**4.9** ULSG Pre-reinsurance DR – Post-reinsurance DR (projected reserves) "Baseline YRT scale" and high credibility





## APF 2019-42 | Survey Results

Reinsurer Reaction	Survey %		
None	1%		
Reactive	64%		
Break-even	29%		
Other	6%		

*Increase YRT premiums by* 

 100% of prescribed mortality margin after 1 year and annually thereafter Includes 10 years of future mortality improvement in implicit margin

*Increase YRT premiums by* 

- 100% of prescribed mortality margin after 1 year and every year thereafter
- Include implicit future mortality improvement margin


*Increase YRT premiums by* 

 100% of the difference between current YRT premium and prescribed mortality immediately and every year thereafter

#### Commentary

- Most responses were reactive and incorporate 100% of the prescribed margin
- Variation in reactive responses was the number of years of mortality improvement included in the margin
- The choice of number of years of future mortality improvement to include in the margin is critical, as

**4.15** ULSG Pre-reinsurance DR – Post-reinsurance DR (projected reserves) "Baseline YRT scale" and high credibility





## **Select Takeaways from YRT Field Test Analysis**

## 4. Differences in modeled reserves are primarily driven by the relationship between the current scale of YRT premiums and PBR mortality (anticipated experience and the level of margin)

- Observed differences in the relationship between the current scale of reinsurance premiums and anticipated mortality as well as the level of mortality margin explain the degree of variability in impacts of reinsurance on modeled reserves across field test participants
- The prescription of triggers (APF 2019-40) and levels of future mortality improvement (APF 2019-41 and 2019-42) reduce differences between the scale of reinsurance premiums and mortality and can be thought of as mechanisms which can be used to define the level of risk shared between parties in the modeled reserve

## 5. Variation in surveyed approaches points to several considerations including level of prescription, modeling complexity, variation in results and others in a long-term solution


- APF 2019-42 has the highest level of prescription. APF 2019-40 allows for more flexibility; however, measures to reduce the variation in results (e.g., "loss ratio" trigger) add additional prescription.
- APF 2019-41 has the most complexity (modeling and theoretical) as it requires projecting YRT premium and claim settlement cashflows using a separate mortality assumption
- APF 2019-40 has the widest variation in modeled range of interpretation "reserve credits" primarily due to survey respondents modeling no change to their current scale. APF 2019-41 has the smallest variation in modeled "reserve credits" but could have larger variations in practice due differences in model implementation.



### **Current Status and Additional Resources**

#### **Current Status**

- Questions and comments regarding the YRT presentations at the Summer NAIC National Meeting are still being accepted by Reggie Mazyck RMazyck@naic.org
- Additional LATF meetings will be scheduled to address any questions from regulators or interested parties










## Life PBR and the treatment of reinsurance Update and insider perspectives

Jason Kehrberg, FSA, MAAA Scott O'Neal, FSA, MAAA Chris Whitney, FSA, MAAA September 1, 2020





## SOCIETY OF ACTUARIES Antitrust Notice for Meetings

Active participation in the Society of Actuaries is an important aspect of membership. However, any Society activity that arguably could be perceived as a restraint of trade exposes the SOA and its members to antitrust risk. Accordingly, meeting participants should refrain from any discussion which may provide the basis for an inference that they agreed to take any action relating to prices, services, production, allocation of markets or any other matter having a market effect. These discussions should be avoided both at official SOA meetings and informal gatherings and activities. In addition, meeting participants should be sensitive to other matters that may raise particular antitrust concern: membership restrictions, codes of ethics or other forms of self-regulation, product standardization or certification. The following are guidelines that should be followed at all SOA meetings, informal gatherings and activities:

- **DON'T** discuss your own, your firm's, or others' prices or fees for service, or anything that might affect prices or fees, such as costs, discounts, terms of sale, or profit margins.
- DON'T stay at a meeting where any such price talk occurs.
- DON'T make public announcements or statements about your own or your firm's prices or fees, or those of competitors, at any SOA meeting or activity.
- DON'T talk about what other entities or their members or employees plan to do in particular geographic or product markets or with particular customers.
- DON'T speak or act on behalf of the SOA or any of its committees unless specifically authorized to do so.
- **DO** alert SOA staff or legal counsel about any concerns regarding proposed statements to be made by the association on behalf of a committee or section.
- **DO** consult with your own legal counsel or the SOA before raising any matter or making any statement that you think may involve competitively sensitive information.
- DO be alert to improper activities, and don't participate if you think something is improper.
- If you have specific questions, seek guidance from your own legal counsel or from the SOA's Executive Director or legal counsel.





#### **Presentation Disclaimer**

Presentations are intended for educational purposes only and do not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually and, unless expressly stated to the contrary, are not the opinion or position of the Society of Actuaries, its cosponsors or its committees. The Society of Actuaries does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented. Attendees should note that the sessions are audio-recorded and may be published in various media, including print, audio and video formats without further notice.







# LIFE PBR AND THE TREATMENT OF REINSURANCE UPDATE AND INSIDER PERSPECTIVES

Valuation Actuary Symposium | Virtual Session

Chris Whitney, FSA, MAAA September 1, 2020



01	Background	i
02	Case study	
03	Industry field test	
04	Key takeaways	<b></b>

© Oliver Wyman









## LIFE PBR IS NOW EFFECTIVE FOR ALL INDIVIDUAL LIFE INSURANCE POLICIES (AND ASSOCIATED REINSURANCE) THAT ARE ISSUED 1/1/2020 OR LATER

#### **Timing and implementation**

- Life PBR became effective 1/1/2017 with an optional three-year implementation period
- PBR implementations are heavily back-loaded and only 23 companies moved a product to PBR in 2017

#### **Applicability**

- Applies to all life new business issued after 1/1/2020 as well as any business moved to PBR during the optional implementation period
- Requirements apply to both reinsurers and direct writers
- Requirements are prescribed in Section 20 of the new valuation manual (VM-20)



- The valuation manual is a living document with revised requirements released on an annual basis
- Terms for adoption are the same as those for the VM itself (requires 42 states/ territories representing 75% of total US life insurance premium)

#### **Calculations**

- PBR is the maximum of three reserve components; a formulaic floor and two modeled reserve components
- Products may be exempt from components of the requirements if they are not sensitive to changes in interest rates











## BACKGROUND

Several sources of guidance exist for the modeling of reinsurance cash flows. Prior to recent changes, the guidance was non-prescriptive and took the form of considerations and required disclosures.

Source	Details				
	The actuary should assume that the counterparty is likely to act efficiently				
VM-20	<ul> <li>The assumptions used may differ between the ceding and assuming company</li> </ul>				
VIII 23	<ul> <li>Additional (outside the cash flow model) stochastic analysis may be required for certain types of reinsurance (i.e. stop-loss)</li> </ul>				
VM-31	Requires a description of assumptions and methodology used to model reinsurance cash flows				
	Recommends consistency between reinsurance assumptions and other assumptions				
PBR ASOP	<ul> <li>Margins should consider the guarantees in the arrangements, past practices of the reinsurer and how the company might respond to different actions the reinsurer could take</li> </ul>				
	<ul> <li>States that "some actuaries will assume less than 100% selection against the company"</li> </ul>				
AAA Practice note	<ul> <li>Recommends analyzing the financial impact on the reinsurer and assuming more selection if the financial impact is significant</li> </ul>				









## RANGE OF PRACTICE

A wide range of practice was observed from early adopters of PBR in regards to the treatment of non-guaranteed reinsurance; regulators began discussing changes to requirements in 2019

Reported reserves were higher post-reinsurance than pre-reinsurance **for some companies**, and **in some cases, the highest reserve changed** between reserve methods pre- and post-reinsurance (e.g. DR highest pre-reinsurance, NPR highest post-reinsurance)

NAIC Valuation Analysis (E) Working Group

A **ceding insurer** might use one set of assumptions to **manufacture a large reserve credit**, while the reinsurer uses a different set of assumptions to calculate a much smaller reserve... We recommend that LATF explore improvements to the Valuation Manual that could **mitigate the risk of this type of gaming.** 

- NAIC Reinsurance (E) Task Force

"




A cohort of new business with \$50MM of first year premium consisting of 10-, 20- and 30-year term products was projected for 30 years

Category	Details		
80 - J.J.	<ul> <li>30 year projection horizon</li> </ul>		
Model	Reserve revalued annually		
	■ Mortality follows 100% of 2015 VBT		
Best estimate assumptions	<ul> <li>Mortality experience is 30% credible with 10 years of sufficient data</li> </ul>		
	<ul> <li>Expenses, commissions and lapses set at industry averages</li> </ul>		
	<ul> <li>Mortality is improved up to each valuation date at 1% per year</li> </ul>		
Prudent estimate assumptions	■ 100% shock lapse at end of level term period		
	■ The NPR uses the 2017 CSO and a valuation interest rate of 4.5%		
D	<ul> <li>DR scenarios are re-generated at each valuation date</li> </ul>		
Reserve assumptions	<ul> <li>Starting assets at each valuation date use the 'direct iteration' approach</li> </ul>		
	<ul> <li>The cohort is assumed to pass the Stochastic Exclusion Test (SET)</li> </ul>		

Assumptions used and products modeled are for an illustrative term portfolio intended to be reasonably representative of products offered in the market today



The gross NPR and DR for this cohort of new business are shown below



The DR starts much higher than the NPR, but the gap closes over time, partially because mortality improvement to date is reflected at future valuation dates










A 50 percent first dollar YRT reinsurance arrangement with the current premium scale set equal to 100 percent of the best estimate mortality assumption was modeled



YRT Scenario 1: No change in rates

YRT Scenario 2: Change rates to eliminate any gain/loss from reinsurance

YRT Scenario 3: Increase rates by 15%








The difference in net reserves under the YRT scenarios modeled is driven by the level of implicit and explicit margin in the VM-20 mortality assumption


The result below is for 35-year-old male, preferred non-tobacco, time 1 valuation



The mortality assumption under VM-20 contains no future mortality improvement and is based on a company-specific prudent assumption grading to a prudent industry table when sufficient data no longer exists



The gross and net reserves resulting from a hypothetical YRT arrangement are shown below for illustrative purposes





- Assume that valuation assumptions are exactly the same between Direct Writer A and Reinsurer
- Final PBR reserve for Direct Writer A is 4.0, the max of NPR, DR and SR on a net of reinsurance basis

	NPR	DR	SR	Final PBR
Gross	5.0	6.0	5.8	6.0
Net	4.0	3.2	3.5	4.0
Ceded	1.0	2.8	2.3	2.0

- 3 Direct Writer A's ceded reserves are equal to 2.0
- Reinsurer's final PBR reserve is calculated using the max of the gross less net components for NPR, DR, and SR and equals 2.8

	NPR	DR	SR	Final PBR
Assumed	1.0	2.8	2.3	2.8

Even with the exact same assumptions, the mechanics of the PBR calculation can result in a difference in ceded reserves and assumed reserves











#### INTERIM SOLUTION AND INDUSTRY FIELD TEST

The Life Actuarial (A) Task Force ("LATF") implemented an "interim solution" for the 2020 Valuation Manual, and requested additional analysis be performed to aid in the selection of a longer-term solution

Solution


#### Guidance

#### Interim solution

- Applies to business issued in 2020+; optional to business on PBR that was issued in 2017-2019
- Non-guaranteed reinsurance is not required to be modeled and the reserve credit for ceded reinsurance (reserve for assumed reinsurance) is equal to the formulaic ½ Cx

#### **Longer-term solutions**

• The scope of the industry field test is limited to three of the proposed amendments that LATF had been discussing prior to the adoption of the "interim solution" (see below) along with two baselines (no change in premiums and ½ Cx)












## 3


#### **INITIAL** ANALYSIS AND FIELD TEST RESULTS

A representative PBR model was used for initial analysis while the industry field test was conducted (December 2019 – March 2020)

#### **Initial analysis**


Shared at Fall 2019 NAIC Meeting and subsequent LATF calls





#### **Industry field test**

Results from industry field test



41 and 2019-42. Some companies responded that they did not believe they would be subject to

PBR either because they had ceased selling new policies or because they met the conditions of one of the exemptions available for PBR. Many indicated that they could not participate due to lack of time and resources. Sixteen companies indicated that they would participate. For various

This report presents results from submissions by 11 participating companies. The set of results presented here include results from seven companies reporting on term policies, and eight reporting on universal life with secondary guarantee (ULSG) policies (four companies reported separately for both policy types). For both term and ULSG policies, one company provided time

zero but not projected reserves. While all results have been examined for consistency, only those

reasons, five of the 16 withdrew without submitting results, leaving us with 11 entities participating. Within the universe of companies subject to PBR, our participants include both smaller and larger companies, all are direct issuers, none are reinsuers.

The remainder of this section focuses on the report developed at the conclusion of the field test which contains results as well as related analysis performed with the representative PBR model










## FIELD TEST REPORT

A report was delivered to LATF in mid-June which covers results of the industry field test and associated survey as well as additional analysis performed using the representative PBR model in light of the results





- **01** PBR continues to evolve, with a potential for changes to be retroactive
- There is a precedent for regulatory intervention in areas where a significant range of practice and/or interpretation exists
- The complexity of principles-based reserve calculations and interplay of assumptions requires significant effort, planning and coordination to evaluate the impact of potential changes

## **OLIVER WYMAN**



